Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Open-Label, Multicenter, Phase III Study to Evaluate the Efficacy and Safety of JYP0322 Versus Crizotinib in Previously Untreated ROS1-Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer

NCT07816380 is registered in ClinicalTrials.gov with Guangzhou JOYO Pharma Co., Ltd as lead sponsor.

NCT NCT07816380
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07816380 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Open-Label, Multicenter, Phase III Study to Evaluate the Efficacy and Safety of JYP0322 Versus Crizotinib in Previously Untreated ROS1-Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Lead sponsor
Guangzhou JOYO Pharma Co., Ltd
Phase
Phase 3
Overall status
Not yet recruiting
Start date
October 30, 2026
Completion date
December 30, 2029
Enrollment
216 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

nsclc (advanced non-small cell lung cancer)